Wed Jun 25 23:00:00 UTC 2025: Okay, here’s a summary of the text, followed by a news article based on it, focusing on the Indian perspective where relevant:
**Summary:**
An investigative report reveals that substandard generic chemotherapy drugs are endangering cancer patients in over 100 countries. The drugs, crucial for treating common cancers, contain incorrect amounts of the active ingredient, rendering them ineffective or dangerously toxic. A study analyzing drug samples from several countries, including some in Africa, found a significant percentage failed quality tests. A major offender is cyclophosphamide manufactured by Indian company Venus Remedies. The problem stems from manufacturers cutting corners in a price-driven market, inadequate regulatory oversight, and flaws in international quality control mechanisms. Patients in low- and middle-income countries, who rely heavily on affordable generic drugs, are particularly vulnerable. The report highlights the devastating consequences for patients who lose valuable treatment windows due to ineffective medication, and the ethical imperative to ensure access to safe and effective drugs globally. The study exposes significant flaws in the global drug supply chain and the need for stronger regulations and oversight to protect vulnerable cancer patients.
**News Article:**
**Substandard Cancer Drugs Put Global Patients at Risk; Indian Manufacturer Under Scrutiny**
**New Delhi, June 26, 2025:** A groundbreaking investigation reveals a disturbing trend of substandard generic chemotherapy drugs circulating globally, posing a serious threat to cancer patients. The study, published today, found that critical medications used to treat common cancers are failing quality tests in alarming numbers, with some containing too little or too much of the active ingredient.
The probe, conducted by the Bureau of Investigative Journalism (TBIJ) in collaboration with The Hindu, uncovered cases of ineffective treatments and potentially fatal side effects in over 100 countries. The study looked at seven common cancer drugs and worked with collaborators in Cameroon, Ethiopia, Kenya and Malawi to analyze drug samples. Shockingly, about one fifth of 189 unexpired samples failed, coming from 20 generic brands made by 17 manufacturers.
Of particular concern is the drug cyclophosphamide, produced by the Indian manufacturer Venus Remedies. All eight samples of this drug tested failed, with some containing less than half the claimed active ingredient. Wondemagegnhu Tigeneh, a clinical oncologist in Addis Ababa, told TBIJ that he has suspicions of some chemotherapy drugs not working because the active ingredient was lower than expected.
The investigation highlights the critical role generic drugs play in cancer treatment, especially in low- and middle-income countries, where costlier treatments are often inaccessible. However, the price-driven market has created a situation where manufacturers are tempted to cut corners, leading to substandard production.
Experts point to inadequate regulatory oversight, both in India and internationally, as a key contributing factor. While India is the world’s largest producer of generic drugs, concerns have been raised about the effectiveness of its regulatory mechanisms and whether manufacturers face adequate punishment for producing substandard drugs. Public health activist Dinesh Thakur claims the Indian government prioritizes protecting the industry over patient safety.
“The implications for Indian patients, and for those in countries relying on Indian-made generics, are deeply troubling,” said Dr. Anya Sharma, a leading oncologist in Delhi. “This investigation underscores the urgent need for stricter quality control measures and greater transparency in the pharmaceutical industry.”
Venus Remedies has disputed the study’s findings, claiming they are “not scientifically plausible” and that internal testing shows the drug to be of good standard. The company also suggested storage conditions might have impacted the results. However, researchers stand by their methodology, stating it is based on regulatory lab practices.
The World Health Organization (WHO) has faced criticism for not adequately addressing the issue, with experts calling for an expansion of its list of essential cancer medicines and stronger mechanisms to ensure drug quality.
The investigation raises serious questions about the safety and efficacy of generic drugs and the urgent need for stronger regulations, improved oversight, and greater accountability to protect cancer patients worldwide.
First Piper 